Optimization of electroconvulsive therapy. Strategies for an adequate convulsion. Role of caffeine;Optimización de la terapia electroconvulsiva. Estrategias para una adecuada convulsión: Papel de la cafeína

Actas Espanolas de Psiquiatria

Volumn 28, Issue 3, 2000, Pages 194-201

  Navines R ^b   Bernardo, M ^a   Martinez Palli G ^b   Blanch, J ^b   Salva J ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

Caffeine; Electroconvulsive therapy; Time of convulsion

Indexed keywords

CAFFEINE;

CHEMICALLY INDUCED DISORDER; ELECTROCONVULSIVE THERAPY; HUMAN; METHODOLOGY; REVIEW; SEIZURE;

CAFFEINE; ELECTROCONVULSIVE THERAPY; HUMANS; SEIZURES;

EID: 0034180332     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Lerer B. The Neurobiology or ECT: The Road Ahead. J ECT 1999;15:1-4.
2. Bernardo M. Terapia Electroconvulsiva: Aplicación Actual. Med Clin (Barc) 1999;113:631-4.
3. Bernardo M, Arrufat F, Catarineru S, Peri JM, Miñarro A, Pintor L, Buisán E, González Monclús E, Ballús C. Pautas actuales en la utilización de la terapia electro-convulsiva en Europa. Psiquiatr Biol 1995;26:213-9.
4. Potter WW, Rudorfer M. ECT, a modern medical procedure. N Engl J Med 1993;12:882-3.
5. Bolwig T. Biological treatments other than drugs. En: Sartorius N, Girolamo G, Andrews G German, Eisengerg L, eds. Treatment of Mental Disorders. A review of Effectiveness. Washington DC: World Health Organization; 1993. p. 91-125.
6. American Psychiatric Association. The practice of Electroconvulsive Therapy: Recommendations for Treatment, Training and Privileging. A task Force Report of the American Psychiatric Association. Washington DC: American Psychiatric Association; 1990. p. 58.
7. Mager PM, Gaugadhar BN, Janakiramaiah, et al. Motor seizure monitoring during electroconvulsive therapy. Br J Psychiatry 1999;174:270-2.
8. Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: Currents Status. J ECT 1999;15:5-26.
9. Arrufat FJ, Bernardo M, Navarro V, Salvà J. Relación entre las propiedades anticonvulsivantes de la terapia electroconvulsiva y su acción terapéutica. Arch Neurobiol 1997;600:37-54.
10. Bernardo M, Pigem R. Terapia Electroconvulsiva. En: Gutierrez M, Ezcurra J, Pichot P, eds. Avances en Psicofarmacología. Ediciones en neurociencias. Barcelona: JR Prous Editores SA; 1994. p. 89-99.
11. Sackeim HA, Devanand DP, Prudic J. Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiat Clin North Am 1991;14:803-43.
12. Abrams R. Electroconvulsive Therapy. Oxford: Oxford University Press; 1988.
13. Roberts MA, Attah JR. Carbamazepine and ECT. Br J Psychiatry 1988;153:418.
14. Krueger RB, Fama JM, Devanand DP, Prudic J, Sackeim HA. Does ECT permanently alter seizure threshold? Biol Psychiatry 1993;33:272-6.
15. Kellner CH, Nixon DW, Bernstein HJ. ECT-drug interactions: a review. Psychopharmacol Bull 1991;27: 595-609.
16. Meldrum BS. The effect of psychotropic drugs on the seizure threshold: animal studies. The psychopharmacology of epilipay. Wiley; 1985. p. 107-17.
17. Nelson JP, Benjamin L. Efficacy and safety of combined ECT and tricyclic antidepressant drugs in the treatment of depressed geriatric patients. Convulsive Ther 1989;5:3211-9.
18. Edwards JG. Antidepressants and seizures: epidemiological and clinical aspects. The psychopharmacology of epilipsy. Wiley; 1985. p. 119-39.
19. Bernardo M, Pigem R. Terapia Electroconvulsiva en la depresión. Barcelona: JR Prous Editores SA; 1995.
20. Muller D. Phenelzine as a potentiator of electroconvulsive therapy. J Ment Sci 1961;107:994.
21. Sargant W. Drugs in the treatment of depression. Br Med J 1961;5221:225-7.
22. Dunlop. Electroshock and monoamine oxidase inhibitors in the treatment of depressed reactions. Dis Nerv Syst 1960;21:130-1.
23. Imlah NW, Ryan E, Harrington JA. The influence of antidepressant drugs on the response to electroconvulsive therapy and on sebsequent relapse rates. Neuropsychopharmacol 1965;4:438-42.
24. Monaco JT, Delaplaine RP. Tranylcypromine with ECT. Am J Psychiatry 1964;120:1003.
25. Remick RA, Jeweesson P, Ford RW. Monoamine oxidase inhibitors in general anesthesia: a reevalutation. Convulsive Ther 1987;3:19-203-
26. Freese KJ. Can patients safely undergo electroconvulsive therapy while receiving monoamine oxidase inhibitors? Convulsive Ther 1985;1:190-4.
27. Itil TM. Convulsive and anticonvulsive properties of neuro-psycho-pharmaca. Mod Probl Pharmacopsychiatry 1970;44:270-305-
28. Isaac L, Schoenbeck R, Bacher J, Skolnick P, Paul SM. Electroconvulsive shock increases endogenous monoamine oxidase inhibitor activity in brain and cerebrospinal fluid. Neurosci Lett 1986;66:257-62.
29. Prockop DJ, Shore PA, Brodie BB. Anticonvulsant properties of monoamine oxidase inhibitors. Ann NY Acad Sci 1959;80:643-51.
30. Wroblewski BA, Guidos A, Leary J, Joseph AB. Control of depression with fluoxetine and antiseizure medication in a brain injured patient. Am J Psychiatry 1992;149:273.
31. Hargrave R, Martínez D, Bernstein AJ. Fluoxetine induced seizures. Psychosomatics 1992; 33:236-9.
32. Ware MR, Stewart RB. Seizures associated with fluoxetine therapy. DICP, Ann Pharmacother 1989,23:428.
33. Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharmacy 1989;8:296-8.
34. Cooper GL. The safey of fluoxetine. Br J Psychiatry 1988;153(Supl 3):77-86.
35. Thompson PM, Zebrowski G, Neuman RS. Alteration of neocortical activity in response to noxious stimulation: participation of the dorsal raphe. Neuropharmacol 1991;30:135-41.
36. Leander JD. Fluoxetine, a selective serotonin-uptade inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide (LY201116). Epilepsia 1992;33:573-5.
37. Haro JM, Bernardo M. Fluoxetina en el tratamiento de un caso de depresión mayor asociado a epilepsia y miastenia gravis. Rev Psiquiatr Fac Med Barna 1994;21:162-4.
38. Sajatovic M, Meltzer HY. The effect of short term electroconvulsive treatment plus neuroleptics in treatment resistant schizophrenia and schizoaffective disorder. Convulsive Ther 1993;9:167-75.
39. Gujavarty K, Greenberg LB, Fink M. Electroconvulsive therapy and neuroleptic medication in therapy resistant positive symptom psychosis. Convulsive Ther 1987;33:185-95.
40. Friedel RO. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients. Psychopharmacol Bull 1986;22:928-30.
41. Siris SG, Glassman AH, Stetner F. ECT and psychotropic medication in the treatment of depression and schizophrenia. Electroconvulsive therapy: biological foundations and clinical applications. New York: Spectrum; 1982. p. 91-111.
42. May PR. Treatment of schizophrenia: a comparative study of five treatment methods. New York: Science House; 1968.
43. Chen G, Ensor CR, Bohner B. Studies of drug effects on electrically induced extensor seizures and clinical implications. Arch Int Pharmacodyn 1968;172: 183-218.
44. Kamal JA, Nadig RS, Joseph T, David J. Effects of calcium channel blockers on experimentally induced seizures in rats. Indian J Exp Biol 1990;28:605-8.
45. Oliver AP, Luchins AJ, Wyatt RJ. Neuroleptic induced seizures: an in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982;39:206-9.
46. Bernardo M, Pigem R. TEC y Esquizofrenia. Esquizofrenia entre la sociogénesis y el condicionamiento biológico II. En: Gutierrez M, Ezcurra J, Pichot P, eds. Monografías de Neurociencias. Capítulo 8. Barcelona: JR Prous Editores SA; 1995.
47. Fink M. Combining Drugs and ECT: Safe and/or effective? Clin Psychopharm 1993;13:85-6.
48. Weiner RD, Coffey CE. Indications for use of ECT. En: France AJ, Hales RE, eds. Review of Psychiatry. Vol 7. Washington DC: Am Psychiat Press; 1988. p. 458-81.
49. Strömgren LS, Dahl J, Fjeldborg N, Thomsen A. Factors influencing seizure duration and number of seizures applied in unilateral electroconvulsive therapy. Anaesthetics and benzodiazepines. Acta Psychiatr Scand 1980;62:158-65.
50. Pettinati HM, Stephens SM, Willis KM, Robin SE. Evidence for less improvement in depression in patients taking benzodiazepines during unilateral ECT. Am J Psychiatry 1990;147:1029-35.
51. Baldessarini RJ, Stephens JH. Lithium carbonate for affective disorders. Arch Gen Psychiatry 1970;22:72-7.
52. Shukla S, Mukherjee S, Decina P. Lithium in the treatment of bipolar disorders associated with epilepsy: an open study. J Clin Psycchopharmacol 1988; 8:201-4.
53. Minabe Y, Emori K, Kurachi M. Effects of chronic lithium treatment on limbic seizure generation in the rat. Psychopharmacology 1988;96:391-4.
54. Cohen MR, Swartz CM. Absence of nimodipine premedication effect on memory after electroconvulsive therapy. Neuropsychobiology 1991;24:165-8.
55. Howie MB, Black HA, Zvara D, McSweeney TD, Martin DJ, Coffman JA. Esmolol reduces autonomie hypersensitivity and length of seizures induced by electroconvulsive therapy. Anesth Analg 1990;71:384-8.
56. McCalll WV, Shelp FE, Weiner RD, Austin S, Harrill A. Effects of labetalol on hemodynamics and seizure duration during ECT. Convulsive Ther 1991;7:5-14.
57. Francis A, Fochtmann L. Caffeine augmentation of electroconvulsive seizures. Psychopharmacology 1994;115:320-4.
58. Rosenquist PB, Vaughn MC, Farah A, Reboussin DM. Effects of caffeine pretreatment on measures of seizures impact. Convulsive Ther 1994;10:181-5.
59. Vaughn W, Reid S, Rosenquist MD, et al. A reappraisal of the role of caffeine in ECT. Am J Psychiatry 1993; 150:1543-5.
60. Coffey CE, Figiel GS, Weiner RD, Saunders WB. Caffeine augmentation of ECT. Am J Psychiatry 1990, 147:579-85.
61. Coffey CE, Weiner RD, Hinkle PE, Cress M, Daughtry G, Wilson WH. Augmentation of ECT seizures with caffeine. Biol Psychiatry 1987;22:637-49.
62. Calev A, Fink M, Petrides G, Francis A, Fochtman L. Caffeine pretreatment enhances clinical efficacy and reduces cognitive effects of electroconvulsive therapy. Convulsive Ther 1993;9:95-100.
63. Hinkel PE, Coffey CE, Weiner RD, Cress M, Christison C. Use of caffeine to lengthen seizures in ECT. Am J Psychiatry 1987;144:1143-8.
64. Shapira Baruch MD, Lerer BB, Gilboa D, Heinz Drexler MD, et al. Facilitation of ECT by caffeine pretreatment. Am J Psychiatry 1987;144:1199-202.
65. Mayo KM, Falkowski W, Jones CA. Caffeine: use and effects in long stay psychiatric patients. Br J Psychiat 1993;162:543-5.
66. Snyder SH, Ssklar P. Behavioral and molecular actions of caffeine: focus on adenosine. J Psychiatry Res 1984;18:91-106.
67. Keith G, Rasmussen MD, Douglas D, Brink P, Soine WH. Different caffeine preparations. Convulsive Ther 1996;12:195-8.
68. Dager SR, Layton ME, et al. Human Brain Metabolic Response to Caffeine and the Effects of Tolerance. Am J Psychiatry 1999;156:229-37.
69. Murray E, Peeling J, Sutherland G. Hippocampal Neurons are Damaged by Caffeine-Augmented Electroschock Seizures. Biol Psychiatry 1996;40:642-7.
70. Krueger RB, Sackeim HA, Gamzu ER. Pharmacological treatment of the cognitive side effects of ECT: a review. Psychopharmacol Bull 1992;28:409-24.
71. Sackeim HA. The cognitive effects of elecroconvulsive therapy. Cognitive disorders: pathophysiology and treatment. New York: Marcel Dekker; 1992. p. 183-228.
72. Nobbler MS, Sackeim HA. Augmentation Strategies in Electroconvulsive Therapy: A Synthesis. Convulsive Ther 1993;9:331-51.
73. Wyler AR, Richey ET, Atkinson RA, Hermann BP. Methohexital activation of epileptogenic foci during acute electrocorticography. Epilepsia 1987;28:490-4.
74. Wilder B. Electroencephalogram activation in medically intractable epileptic patients. Arch Neurol 1971;25:415-26.
75. Swartz CM. Propofol anesthesia in ECT. Convulsive Ther 1992;8:262-6.
76. Hodkinson BP, Frith RW, Mee EW. Propofol and the electroencephalogram. Lancet 1987;2:1518.
77. Villalonga A, Bernardo M, Gomar C, Fita G, Escobar R, Pacheco M. Cardiovascular Response and Anesthetic Recovery in Electroconvulsive Therapy with Propofol or Thiopenthal. Convulsive Ther 1993;9: 108-11.
78. Rampton AJ, Griffinnnn RM, Stuart CS, Durcan JJ, Juddy NC, Abbott MA. Comparison of methohexital and propofol for electroconvulsive therapy: effects on hemodynamic responses and seizure duration. Anesthesiol 1989;70:412-7.
79. Dwyer R, McCaughey W, Lavery J, McCarthy G, Dundee JW. Comparison of propofol and methohexitone as anaesthetic agents for electroconvulsive therapy. Anaesth 1988;43:459-62.
80. Al-Hader A, Hasan M, Hasan Z. The comparative effects of propofol, thiopental, and diazepam, administered intravenously, on pentylenetetrazol seizure threshold in the rabbit. Life Sci 1992;51:779-86.
81. Nobler MS, Sackeim HA, Solomou MS, Luber B, Devanand DP, Prudic J. EEG manifestations during ECT: effects of electrode placement and stimulus intensity. Biol Psychiatry 1993;34:321-30.
82. Stern RA, Nevels CT, Shelhorse ME, Prohaska ML, Mason GM, Prange AJ. Antidepressant and memory effects of combined thyroid hormone treatment and electroconvulsive therapy: preliminary findings. Biol Psychiatry 1991;30:623-7.